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Abstract
Background: Mutations of the glucocerebrosidase (GBA) gene have reportedly been associated with Parkinson
disease (PD) in various ethnic populations such as Singaporean, Japanese, Formosan, Canadian, American,
Portuguese, Greek, Brazilian, British, Italian, Ashkenazi Jewish, southern and southwestern Chinese. The purpose of
this study is to determine in central China whether or not the reported GBA mutations remain associated with PD.
Methods: In this project, we conducted a controlled study in a cohort of 208 central Chinese PD patients and
298 controls for three known GBA mutations (L444P, N370S and R120W).
Results: Our data reveals a significantly higher frequency of L444P mutation in GBA gene of PD cases (3.4%)
compared with the controls (0.3%) (P = 0.007, OR = 10.34, 95% CI = 1.26 - 84.71). Specifically, the frequency of
L444P mutation was higher in the late onset PD (LOPD) cases compared with that in control subjects. The N370S
and R120W mutations were detected in neither the PD group nor the control subjects.
Conclusions: Our observations demonstrated that the GBA L444P mutation confers genetic risk for PD, especially
LOPD, among the population in the central China area.
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Background
Parkinson disease (PD) is the second most common
neurodegenerative disorder. The disease is pathologically
characterized by the degeneration of dopaminergic neu-
rons in the nigro-striatal system, leading to progressive
movement impairments, such as rigidity, bradykinesia,
impaired balance and tremor at rest. However, the etiology
and pathogenesis of this disorder are not yet thoroughly
understood. Besides aging and environmental risk factors,
genetic variation is also considered to be a relevant factor
for PD risk. Additionally, more than 9 genes have been
confirmed as PD-linked genes [1].
The Glucocerebrosidase (GBA) gene, located at chromo-
some 1q21, encodes the enzyme glucocerebrosidase.
Mutations in the GBA gene are known to cause Gaucher
disease (GD), which is an autosomal recessive glycolipid
storage disorder with multisystemic manifestations [2]. It
has been previously reported that parkinsonian symptoms
could be observed in Gaucher patients, and increased PD
incidence could be found in Gaucher families [3]. Simul-
taneously, increased occurrence of GBA mutations can
be detected from PD brain samples [4]. Subsequently,
there has been increasing documentation of the associ-
ation between the GBA gene and PD in different ethnic
groups, yielding contradictory results. Among these stud-
ies, the GBA mutations showed no significant difference
between PD and controls in Venezuela and Norway [5,6].
However, previous studies indicate that a high ratio of
GBA mutation frequency is related to increased PD risk in
Singaporean, Japanese, Formosan, Canadian, American,
Portuguese, Greek, Brazilian, British, Italian, Ashkenazi
Jewish, southern and southwestern Chinese populations
[5-20]. Specifically, three GBA mutations, L444P, N370S
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in Non-Ashkenazi Jewish Patients [21].
N370S is reportedly the most common mutation
among Ashkenazi Jewish Patients, while it is the second
most frequent mutation after L444P in Non-Ashkenazi
Jewish Patients [21]. In the Asian studies, only one has
demonstrated that N370S allele might be associated with
LOPD in the Chinese Han population [11,13,14,16]. No
R120W mutation has been detected in Ashkenazi Jewish
Patient population. However, a significant association
between R120W mutation and PD has been observed in
Non-Ashkenazi Jewish Patients as well as in Japanese
patients [21].
Overall, little is known about the correlation between
these GBA gene mutations (L444P, N370S and R120W)
and PD in the central China area, which includes six
mostly agricultural provinces of Hunan, Hubei, Jiangxi,
Henan, Shanxi and Anhui. We argue that the central
China area should be of particular interest since recent
epidemiological studies suggest an association of envir-
onmental toxins such as rotenone and other pesticides
with the higher incidence of sporadic PD in rural areas
[22-24]. As such, our study aims at examining the pos-
sible association between GBA L444P, N370S or R120W




This study was approved by the Ethical Committee of
Tongji Medical College, Huazhong University of Science
(TJMC & HUST). The technology ethics and written
informed consents were obtained from all subjects. A
total of 208 PD patients [136 males, 72 females, mean
age 56.75 ± 12.94 years, range 25 - 83] were recruited
from the Department of Neurology, Union Hospital,
TJMC & HUST. Diagnosis was conducted in accordance
with UK-Parkinson’s Disease Society Brain Bank criteria.
We divided these patients into two groups: early onset
PD (EOPD, age at onset < 50 years, 72 subjects) and
LOPD (age at onset >= 50 years, 136 subjects) [25]. Con-
currently, 298 controls [194 males, 104 females, mean age
51.62 ± 11.33 years, range 23 - 90] were recruited from
the Department of Neurology, Union Hospital, TJMC &
HUST (see Additional file 1 for the demographic infor-
mation of patients and controls). The controls were
selected from subjects whose physical examination
revealed no evidence of PD, without a family history of
PD, and no evidence of Alzheimer’s disease, cerebrovas-
cular disease or any other neurological disorder. There is
no blood relationship between controls and patients. All
PD and control individuals are residents of the central
China area.
Genetic analysis
Mutation screening was performed using the polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) method. Peripheral blood (5 ml) was col-
lected from each participant and placed in EDTA-
containing vacuum tubes. Genomic DNA was extracted
using the phenol chloroform extraction method, stored
at -20°C to await further processing. The optional para-
meters for 25 μl PCR reaction system were 12.5 μl2x
Power Taq PCR MasterMix (Bioteke Corporation, Beijing,
China), 1 μl primers (10 pmol/μl), 1 μl DNA templates
(30 ng/μl) and 9.5 μl ddH2O. The L444P, N370S and
R120W primers were obtained from previous studies
[15,17]. The PCR products were digested overnight with
NciI, XhoI, NciI, respectively, at 37°C, with the effective
digestion system of 15 μ1 including 10 μl DNA solution
and 10 U enzyme.
The digestion product was electrophoresed on 2%
agarose gel and visualized by Sybr-greenI. The L444P
and N370S mutations create split clips with the use of
the NciI and XhoI restriction enzymes, respectively. The
R120W mutation cancels a native restriction site for
Ncil. All mutated alleles were notarized by DNA direct
sequencing of PCR products from a second amplifica-
tion. The DNA sequences were analyzed using Chromas,
Version 2.22.
Statistical analysis
Statistical differences of carrier rates among PD and con-
trol groups were analyzed by means of the Fisher test.
The odds ratio of different alleles across EOPD and
LOPD groups were analyzed with both the Mantel-
Haenszel test and meta-analysis. The difference of age at
onset between carriers and non-carriers or total patients
was analyzed by using the two tailed Student’s test. Odds
ratio (OR) with 95% confidence intervals (95% CI) was
employed to test the association between the GBA muta-
tion and PD. Results were presented as mean ± standard
error. P < 0.05 is considered to be statistically significant.
Results
The GBA L444P mutation is correlated with an increased
PD risk
In 208 PD patients, GBA mutations were found in
7 (3.4%) patients by PCR-RFLP (Additional file 2) and
confirmed by DNA sequencing (Table 1 and Additional
file 2B and 2C). The results of the PCR-RFLP analysis
and DNA sequencing were in agreement (Additional
file 2). Moreover, all GBA mutations were heterozygous
for L444P. Among the 298 control subjects, only 1 (0.3%)
had a mutation, and this mutation was also heterozygous
for L444P. No N370S or R120W mutation was detected
in any PD patient or control subject. The difference of
GBA L444P mutation frequencies in PD patients and
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Moreover, there was a correlation between increased PD
risk and higher GBA L444P mutation (OR = 10.34, 95%
CI: 1.26 - 84.71). The distributions and association of
GBA mutations in patients and controls are shown in
Table 1.
Higher frequency of L444P mutation is associated with
LOPD
Following age-stratification, a significantly higher fre-
quency of L444P mutation was found in LOPD cases
compared with that in controls (OR = 13.71, 95% CI:
1.63 - 115.00, *P = 0.005, Table 2). However, no detect-
able difference was observed between EOPD subjects
and controls (OR = 4.18, 95% CI: 0.26 - 67.69, P = 0.352,
Table 2).
Gender or age distribution of mutation carriers and non-
carriers showed no difference
Among all PD patients, no significant difference in age
was found between the L444P mutation carriers and non-
carriers. The average age was 56.14 ± 8.34 years in the car-
riers and 56.78 ± 13.08 in the non-carriers (P = 0.899,
Table 3). Following age-stratification, no difference was
observed between carriers and non-carriers in LOPD cases
(58.00 ±7.38 years vs. 64.73 ± 8.21 years; P = 0.051,Table 3)
and EOPD subjects (45.00 years vs. 42.21 ± 5.66 years,
P = 0.626, Table 3). There was no significant difference
observed in gender between mutation carriers and non-
carriers (P = 0.732, Table 3).
Discussion
Central China is relatively characterized by the six pro-
vinces of Hunan, Hubei, Jiangxi, Henan, Shanxi and
Anhui, all largely agricultural. Epidemiological study
suggests that living in a rural area, drinking well water,
farming and exposure to pesticides may be significant
risk factors in the development of PD [21]. Central
China is considered to be the cradle of agriculture in
China. Importantly, the population density in this region
is very high. Previous epidemiological study also showed
that the prevalence of PD in South-Central (including
Central China area) China is higher compared to other
areas of China [21]. In this study, we investigated the
association of 3 GBA gene mutations (L444P, N370S
and R120W) with central Chinese PD patients. The
frequency of the GBA mutations in PD patients was
3.4%. This statistically significant difference in GBA
mutations between PD patients and control subjects sug-
gests that the GBA gene is a susceptibility gene in central
China and GBA mutation may increase the risk of PD.
High frequency of GBA mutations was found in LOPD
cases. There was no significant difference due to gender
between mutation carriers and non-carriers. Addition-
ally, the average age at onset of PD carriers between
carriers and non-carriers was insignificant.
GBA L444P mutation has reportedly been associated
with PD in various ethnic groups [7,9-16,19,20,26]. In a
previous study, L444P was identified as the most fre-
quent mutation in non-Ashkenazi Jewish patients [21].
However, there was no significant difference in PD
patients and controls in other ethnic groups diagnosed
with the L444P mutation (Toft and others 2006; Eblan
and others 2006). In this study, the GBA mutations of
PD subjects were all heterozygous for L444P, and there
was a significant difference between the results of PD
patients and controls. Together with the results of two
other studies in Southern and Southwestern regions of
China [10,13], these data provide evidence that the
L444P mutation confers risk for PD in China. Further-
more, following age-stratification, this study revealed a
higher frequency of the GBA L444P mutations in LOPD
patients compared with that in the control group. This
result is different from that of other studies which show-
ing GBA gene mutations occurred in EOPD rather than
LOPD [10,21]. The discrepancy may be attributed to dif-
ferent genetic backgrounds or environmental factors
among others.
Table 1 Distributions and association of GBA mutations in patients and controls
Mutation PD(n/N) Controls(n/N) Odds ratio 95% CI p value




Table 2 Differences in age-stratification between mutation carriers and non-carriers
Subgroup PD (n/N) Controls (n/N) Odds ratio 95% CI p value
EOPD 1/72 1/298 4.18 0.26-67.69 0.352
LOPD 6/136 1/298 13.71 1.63-115.00 0.005*
*Fisher’s exact test.
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and non-Jewish GD patients, is rarely presented in Asian
patients [27]. Similar to previous findings, our result
showed that N370S mutation was absent in both PD
patients and control subjects [13,21]. A recent study indi-
cated that N370S might affect age of onset and may also
contribute to LOPD susceptibility in Chinese Han popu-
lations [8]. There were several explanations for the vari-
ous research results, including the large influx of a Jewish
population to China during World War II, and the pos-
sible introduction of the gene mutation by traders using
the Silk Road in the distant past [27]. It is also conceiv-
able that the N370S mutation may exist only in specific
areas of China and/or some other Asian regions. More
research will be necessary to address the question of
whether the mutations exist in different areas of China.
R120W is considered as the third most common muta-
tion of non-neuropathic GD. A previous Japanese study
determined that R120W was prevalent and significantly
associated with PD (15/534, P < 0.001) [11]. A Taiwan
study found one R120W mutation in PD patients as well
[15]. However, the association between PD and the GBA
R120W mutation was not significant. No R120W muta-
tion has been found in the Ashkenazi Jewish PD patient
population. Our study was the first to explore the associ-
ation between the R120W mutation and PD in Mainland
China. Similar to the case of the Ashkenazi Jews, no
R120W mutation was found in our PD patients or con-
trols [11,15]. Different ethnic groups and environmental
factors among different areas may explain the discrepancy.
The L444P mutation, resulting from a T to C transition
in nucleotide 6092 of the GBA gene, can make leucine
into proline, which leads to the imperfection of glucocer-
ebrosidase. The mechanism of GBA mutations conferring
risk for PD is not yet completely understood. First, de-
crease in glucocerebrosidase activities has a role in the
pathogenesis of PD [11]. Second, GBA mutations contrib-
ute to protein misfolding [28], leading to lysosomes and
ubiquitin-proteasome system dysfunction which cause
neurodegeneration [29]. Third, GBA mutations may po-
tentially accumulate the substrates glucocerebroside and/
or glucosylsphingosine, disrupting membrane binding of
alpha-synuclein, which prevents the formation of fibrillar
protein structures of alpha-synuclein [29,30]. Finally, the
fluctuation in the levels of ceramide, the result of
homozygous or heterozygous GBA mutations, is consid-
ered to cause Parkinsonism as well [18]. More research
evidence is needed to confirm the mechanism of these
hypotheses. Potential molecular therapies and genetic
counseling of patients and family members may be
developed for PD patients with GBA mutations once
the mechanism for the association is determined.
Additionally, we acknowledge that our case–control re-
sult may be susceptible to bias because of the test method
and sample size. In our study, we chose to screen mainly
by restriction digest rather than by sequencing. It has been
reported that as many as 45% of mutant alleles can be
missed among non-Ashkenazi Jewish patients (20% among
Ashkenazi Jewish patients) when screening for only the
N370S and L444P mutations instead of the whole gene
[21]. Replication of genetic associations in various popula-
tions is essential to establish specific genetic contribution
to the disease. The purpose of this study is to confirm the
contribution of GBA mutations to PD etiology, although
we may miss some mutant alleles by restriction digest for
only three mutations. Moreover, given the small sample
size (208 cases and 298 controls, 136 LOPD and 72
EOPD), replications of the positive associations in the
Chinese population is warranted. We will increase the
sample size and explore new GBA gene mutations by se-
quencing the whole gene in the next step.
Conclusions
In summary, we presented GBA L444P mutation as a
relatively prevalent genetic risk factor for sporadic PD.
GBA may act as a novel therapeutic target for PD and
may be used in the early diagnosis of PD in the future.
With further research, we expect to be able to provide
new avenues for developing therapeutic alternatives for
PD based on the GBA gene.
Additional files
Additional file 1: The demographic information of patients and
healthy controls.
Additional file 2: PCR analysis and Sequence of the L444P mutation
in Patients with PD. (A) The restriction enzyme NciI digests a 638 bp
PCR product, producing two fragments of 536 bp and 102 bp. The
digestion of wild-type PCR product and L444P mutation with a Low
Range DNA Ladder are shown in (B) and (C). (B) Normal Sequence of the
GBA gene; (C) The L444P Mutation in the GBA gene. The arrows indicate
the position of the mutation.
Abbreviations
GBA: Glucocerebrosidase; PD: Parkinson’s disease; LOPD: Late Onset of
Parkinson’s Disease; EOPD: Early Onset of Parkinson’s Disease; GD: Gaucher
disease; TJMC & HUST: Tongji Medical College, Huazhong University of
Science; PCR-RFLP: Polymerase chain reaction-restriction fragment length
polymorphism; OR: Odds ratios.
Table 3 Age at onset and gender of PD patients
Carriers Non-carriers p value
Age at onset (year)
PD 56.14±8.34 56.78±13.08 0.899
LOPD 58.00±7.38 64.73 ± 8.21 0.051
EOPD 45.00 42.21 ± 5.66 0.626
Gender
Male (%) 5(71.4) 131(65.2) 0.732
Female (%) 2(28.5) 70(34.8)
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